w66最给利老牌

VOLUNTARY ANNOUNCEMENT - COMPLETION OF PATIENT ENROLLMENT IN PHASE III CLINICAL TRIAL OF RECOMBINANT HUMAN COAGULATION FACTOR VIIA FOR INJECTION

VOLUNTARY ANNOUNCEMENT - IND APPLICATION OF INNOVATIVE MEDICINE “TCC1727” FILED WITH AND ACCEPTED BY FDA

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 NOVEMBER 2022

VOLUNTARY DISCLOSURE - 2022 THIRD QUARTER UPDATE

RESIGNATION OF EXECUTIVE DIRECTOR

LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 OCTOBER 2022

NEXT DAY DISCLOSURE RETURN